Healthcare Industry News: MRIdian
News Release - April 17, 2019
ViewRay Partners with Largest Independent Distributor in Australia and New Zealand to Bring Benefits of MRI-Guided Radiation Therapy to the RegionDevice Technologies Australia to Help Expand Global MRIdian Adoption
CLEVELAND, April 17, 2019 -- (Healthcare Sales & Marketing Network) -- ViewRay, Inc. (Nasdaq: VRAY) and Device Technologies Australia Pty Ltd (Device Technologies) announced today a partnership in which Device Technologies, the largest independent distributor in Australasia, will market, sell, and support ViewRay's MRIdian MRI-guided radiation therapy system.
"Device Technologies is the ideal partner to bring the benefits of the MRIdian System to one of the biggest and best healthcare markets in the world," said Jim Alecxih, Chief Commercial Officer at ViewRay. "Device Technologies has successfully sold, implemented and supported many other high-tech medical devices, so we're confident given the growing excitement around MRI-guided radiation therapy, that they will deliver equally impressive results with MRIdian."
MRIdian provides continuous high-contrast imaging of soft tissue during radiation therapy treatment to help clinicians position the patient, track tumor and anatomical motion, and accurately target treatment. MRIdian also enables on-table adaptive therapy, which allows clinicians to adapt to changes and movement in the patient's anatomy in real-time while the patient is being treated, bringing even greater precision to radiation delivery.
"We're delighted to be including ViewRay's MRIdian in the portfolio of high-end innovative products for distribution in Australia and New Zealand," said Mick Trevaskis, CEO of Device Technologies Australia Pty Ltd. "We always put our patients first, and MRIdian's simultaneous MRI imaging and radiation therapy provides highly accurate delivery of radiation to the patient, which helps enable an optimal clinical outcome in a shorter timeframe."
Device Technologies is dedicated to improving patients' lives through the supply of leading-edge technology and services to Australian and New Zealand hospitals and healthcare professionals. Device Technologies continues to grow, with more than 250 trusted brands from the world's most innovative medical companies and 850 highly skilled staff, making it the largest independent distributor in Australasia. Customer service and patient care remain critical core values.
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
About Device Technologies
Since 1992, Device Technologies Australia Pty Ltd has been dedicated to improving patients' lives through the supply of leading edge technology and services to Australian and New Zealand hospitals and healthcare professionals. Device Technologies continues to grow, with over 250 trusted brands from the world's most innovative medical companies, and 850 highly skilled staff to make it now the largest independent distributor in Australasia. Customer service and patient care remain as their critical core values.
Intended Use: The MRIdian Linac System, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated.
Forward-Looking Statements: This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include, but are not limited to references to future MRIdian installations, clinical value and outcomes. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, government and regulatory uncertainty, including but not limited to obtaining authorizations to market and new tariffs and trade restrictions, and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsEuropean Symposium to Advance Adoption of MRI-Guided Radiation Therapy
Patient Treatments with ViewRay's MRIdian Linac Begin in New England
ViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers